Group 1 - The discussion among representatives focused on the growth and nurturing of unicorn companies, highlighting the importance of selecting the right industry "track" for success [3][5] - The representatives emphasized the potential of the biopharmaceutical industry in China, particularly in the context of the ongoing innovation wave in drug development [3][5] - The representatives shared their experiences in innovation and research, with one company holding over 300 independent intellectual property rights and another achieving significant advancements in third-generation semiconductor materials [6][5] Group 2 - The representatives discussed the importance of collaboration with academic institutions to overcome technological challenges, with examples of partnerships with universities and research institutes [6] - The conversation underscored the need for talent in innovation, suggesting that companies should build their own research teams while also leveraging external expertise [6] - The insights gained from this discussion provided motivation and confidence for companies aiming to transition into unicorn status [6]